

Filippo Ballerini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1894779/publications.pdf>

Version: 2024-02-01

39
papers

955
citations

567281

15
h-index

434195

31
g-index

39
all docs

39
docs citations

39
times ranked

1611
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | The Longest Persistence of Viable SARS-CoV-2 With Recurrence of Viremia and Relapsing Symptomatic COVID-19 in an Immunocompromised Patient—A Case Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab217. | 0.9 | 64 |
| 2 | Feasibility of Single-Port Laparoscopic Lymph Node Biopsy for Intra-Abdominal Lymphoma: A Case Series. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2021, 31, 458-461. | 1.0 | 2 |
| 3 | Pre-transplant minimal residual disease assessment and transplant-related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation. <i>European Journal of Haematology</i> , 2021, 107, 573-582. | 2.2 | 7 |
| 4 | Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3-ITD in NPM1 Mutated AML, Irrespectively of FLT3-ITD Allelic Burden. <i>Cancers</i> , 2021, 13, 34. | 3.7 | 10 |
| 5 | Adding Romidepsin to CHOEP in First Line Treatment of Peripheral T-Cell Lymphomas Does Not Improve the Response Rate: Final Analysis of Phase II PTCL13 Study. <i>Blood</i> , 2021, 138, 134-134. | 1.4 | 3 |
| 6 | Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas. <i>Leukemia and Lymphoma</i> , 2020, 61, 84-90. | 1.3 | 7 |
| 7 | Prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like immunophenotype in cytogenetically normal acute myeloid leukemia patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 1695-1701. | 1.3 | 4 |
| 8 | Hodgkin's lymphoma: post- autologous transplantation consolidation therapy. <i>Acta Biomedica</i> , 2020, 91, 23-29. | 0.3 | 5 |
| 9 | Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with <i>NPM1</i> mutation: from definition of molecular relapse to MRD-driven salvage approach. <i>British Journal of Haematology</i> , 2019, 186, e223-e225. | 2.5 | 9 |
| 10 | A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia. <i>Leukemia Research</i> , 2019, 86, 106223. | 0.8 | 7 |
| 11 | Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information. <i>British Journal of Haematology</i> , 2019, 184, 457-460. | 2.5 | 13 |
| 12 | Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study). <i>Oncologist</i> , 2018, 23, 1033-1038. | 3.7 | 3 |
| 13 | Performance of serum (1,3)- β -glucan screening for the diagnosis of invasive aspergillosis in neutropenic patients with haematological malignancies. <i>Mycoses</i> , 2018, 61, 650-655. | 4.0 | 11 |
| 14 | Prompt detection of asparaginase inactivation is crucial to optimize treatment efficacy also in aggressive lymphomas. <i>Hematological Oncology</i> , 2018, 36, 498-499. | 1.7 | 0 |
| 15 | A blastic plasmacytoid dendritic cell neoplasm-like phenotype identifies a subgroup of <i>npm1</i> mutated acute myeloid leukemia patients with worse prognosis. <i>American Journal of Hematology</i> , 2018, 93, E33-E35. | 4.1 | 16 |
| 16 | Combining flow cytometry and <i>WT1</i> assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia. <i>Haematologica</i> , 2017, 102, e348-e351. | 3.5 | 26 |
| 17 | Good tolerability of high dose colistin-based therapy in patients with haematological malignancies. <i>Infection</i> , 2017, 45, 505-511. | 4.7 | 3 |
| 18 | High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients. <i>American Journal of Hematology</i> , 2016, 91, 755-762. | 4.1 | 18 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | SIRT6 Inhibition As a Novel Approach for Treating Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 5222-5222. | 1.4 | 0 |
| 20 | Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma. <i>BioMed Research International</i> , 2015, 2015, 1-8. | 1.9 | 13 |
| 21 | IL-1 β -releasing human acute myeloid leukemia blasts modulate natural killer cell differentiation from CD34+ precursors. <i>Haematologica</i> , 2015, 100, e42-e45. | 3.5 | 14 |
| 22 | A Novel Synthetic Lethal Approach Targeting SIRT6 in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 1375-1375. | 1.4 | 1 |
| 23 | Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia. <i>Annals of Hematology</i> , 2014, 93, 2011-2018. | 1.8 | 15 |
| 24 | Unmanipulated Haploidentical Bone Marrow Transplantation and Posttransplantation Cyclophosphamide for Hematologic Malignancies after Myeloablative Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 117-122. | 2.0 | 324 |
| 25 | Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia. <i>Leukemia Research</i> , 2013, 37, 1606-1611. | 0.8 | 36 |
| 26 | De novo AML patients with favourable "intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened "GO question". <i>Annals of Hematology</i> , 2013, 92, 1309-1318. | 1.8 | 3 |
| 27 | Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study. <i>Hematological Oncology</i> , 2013, 31, 179-182. | 1.7 | 20 |
| 28 | Nucleophosmin gene-based monitoring in de novo cytogenetically normal acute myeloid leukemia with nucleophosmin gene mutations: comparison with cytofluorimetric analysis and study of Wilms tumor gene 1 expression. <i>Leukemia and Lymphoma</i> , 2012, 53, 2214-2217. | 1.3 | 9 |
| 29 | WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2011, 52, 1961-1969. | 1.3 | 37 |
| 30 | Amphotericin B Lipid Complex in the Management of Invasive Fungal Infections in Immunocompromised Patients. <i>Clinical Drug Investigation</i> , 2011, 31, 745-758. | 2.2 | 18 |
| 31 | Short-Term Thalidomide Incorporated Into Double Autologous Stem-Cell Transplantation Improves Outcomes in Comparison With Double Autotransplantation for Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2009, 27, 5001-5007. | 1.6 | 46 |
| 32 | The addition of radiotherapy to chemotherapy does not improve outcome of early stage Hodgkin's lymphoma patients: a retrospective long-term follow-up analysis of a regional Italian experience. <i>Annals of Hematology</i> , 2009, 88, 855-861. | 1.8 | 9 |
| 33 | Molecular analysis of the Imatinib-induced complete cytogenetic response in chronic myelogenous leukemia. <i>Leukemia and Lymphoma</i> , 2006, 47, 1348-1351. | 1.3 | 4 |
| 34 | Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies. <i>Oncology Reports</i> , 2005, 14, 933-40. | 2.6 | 10 |
| 35 | Role of Liposomal Daunorubicin, Fludarabine and Cytarabine (FLAD) in the Salvage Therapy of Adult Acute Lymphoblastic Leukemia. <i>Leukemia and Lymphoma</i> , 2004, 45, 2527-2530. | 1.3 | 1 |
| 36 | Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia. <i>Annals of Hematology</i> , 2004, 83, 696-703. | 1.8 | 26 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Quality of life and brain function following high-dose recombinant human erythropoietin in low-risk myelodysplastic syndromes: a preliminary report. <i>European Journal of Haematology</i> , 2004, 72, 113-120. | 2.2 | 28 |
| 38 | Thalidomide in Myelofibrosis with Myeloid Metaplasia: A Pooled-analysis of Individual Patient Data from Five Studies. <i>Leukemia and Lymphoma</i> , 2002, 43, 2301-2307. | 1.3 | 90 |
| 39 | Thalidomide in agnogenic and secondary myelofibrosis. <i>British Journal of Haematology</i> , 2001, 115, 313-315. | 2.5 | 43 |